Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 10/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981592 | 0.90 | SPHK1 (0.47) | ESR2SPHK1SPHK2 | |
| SCHEMBL12926323 | 0.87 | SPHK1 (0.59) | ALDH1A1LMNAMAPTSPHK1CYP2C9 | |
| SCHEMBL14141516 | 0.87 | SPHK1 (0.49) | ALDH1A1LMNAMAPTSPHK1CYP2C9 | |
| SCHEMBL12736263 | 0.87 | ALDH1A1 (0.49) | ESR2ALDH1A1LMNAMAPTSPHK1 | |
| SCHEMBL12926310 | 0.84 | MAPT (0.44) | ALDH1A1LMNAMAPTCYP2C9MEN1 | |
| SCHEMBL12736264 | 0.83 | SPHK1 (0.49) | ALDH1A1LMNAMAPTSPHK1CYP2C9 | |
| SCHEMBL7912602 | 0.83 | SPHK1 (0.40) | ESR2ALDH1A1LMNAMAPTSPHK1 | |
| SCHEMBL7912597 | 0.83 | SPHK1 (0.40) | ESR2ALDH1A1LMNAMAPTSPHK1 | |
| SCHEMBL12736445 | 0.83 | ALDH1A1 (0.46) | ESR2ALDH1A1LMNAMAPTSPHK1 | |
| SCHEMBL9267879 | 0.82 | DRD2 (0.45) | ESR2ALDH1A1LMNAMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354147-B2 | Polymerizable liquid crystal compound, composition and polymer | JNC CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20110001088-A1 | Polymerizable Liquid Crystal Compound, Composition and Polymer | CHISSO CORPORATION (JP) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110001088-A1 | Polymerizable Liquid Crystal Compound, Composition and Polymer | CCNT1, H1-0, CCNA1 | ESR2 3078/4885ALDH1A1 1447/4885LMNA 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.